Đánh giá kết quả hóa xạ trị điều biến liều ung thư thực quản 1/3 trên tại Bệnh viện Ung bướu Hà Nội

To evaluate treatment outcomes of concurrent chemoradiation with intensity modulated radiotherapy (IMRT) in the upper thirds esophageal cancer patients at Hanoi Oncology Hospital . Patients and Methods: A pre-post interventional study on 31 upper thirds esophageal cancer patients treated by concurrent IMRT/chemotherapy with CF regimen. Results: There were 83.9% patients having improvement in dysphagia. The complete and partial responses were 19.4% and 61.2% respectively. No significant association was seen between response rate and disease stages, radiation doses, and chemo doses. Response rates categorized by RECIST appeared significantly different across stages, and radiation dose with p=0.001 và p=0.003, but not significantly different across chemo doses (p=0.084). The most common side effects were dermatitis, esophagitis, vomiting, amenia, neutropenia with the toxicity mostly at grade I-II. Conclusion: The concurrent chemoradiation with IMRT in upper thirds esophageal cancer is a safe therapy, gives high efficacy, reduces dose to normal surrounding tissues, with acceptable side effects.